4-(4-methylpiperazin-1-yl)quinazolin-2-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-(4-methylpiperazin-1-yl)quinazolin-2-amine
• 化学式: C₁₃H₁₇N₅
• mdl: MFCD25022743
• 分子量: 243.311
• InChiKey: GORRKRHEHKVTEB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.384
• 拓扑面积：
  58.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2,4-喹唑啉二酮 在 sodium azide 、 氢气 、 N,N-二异丙基乙胺 、 三氯氧磷 作用下， 以 四氢呋喃 、 N-甲基吡咯烷酮 、 乙酸乙酯 为溶剂， 反应 5.25h， 生成 4-(4-methylpiperazin-1-yl)quinazolin-2-amine
  参考文献：
  名称：

  Ligand based design of novel histamine H4 receptor antagonists; fragment optimization and analysis of binding kinetics

  摘要：

  The histamine H-4 receptor is a G protein-coupled receptor that has attracted much interest for its role in inflammatory and immunomodulatory functions. In our search for new H4R ligands, a low affinity isoquinoline fragment was optimized to 7-(furan-2-yl)-4-(piperazin-1-yl)quinazolin-2-amine (VUF11489), as a new H4R antagonist. Analysis of its binding kinetics at the human H4R showed this compound to have a very different dissociative half-life in comparison with reference antagonist JNJ7777120. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.10.104

文献信息

• SUBSTITUTED HETEROCYCLIC COMPOUNDS
  申请人：ZHUO Jincong

  公开号：US20100240671A1

  公开（公告）日：2010-09-23

  The present invention relates to substituted heterocyclic compounds of Formula I or XI: or pharmaceutically acceptable salts or N-oxides or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are histamine II4 receptor inhibitors useful in the treatment of histamine II4 receptor-associated conditions or diseases or disorders including, for example, inflammatory diseases or disorders, pruritus, and pain.

  本发明涉及式I或XI的取代杂环化合物： 或其药用可接受的盐或N-氧化物或季铵盐，其中所述成员在此提供，并且它们的组合物和使用方法，这些方法是组胺H24受体抑制剂，用于治疗组胺H24受体相关的疾病或疾病，包括例如炎症性疾病或疾病，瘙痒和疼痛。
• SUBSTITUTED HETEROCYLIC COMPOUNDS
  申请人：Incyte Corporation

  公开号：US20130296327A1

  公开（公告）日：2013-11-07

  The present invention relates to substituted heterocyclic compounds of Formula I or XI: or pharmaceutically acceptable salts or N-oxides or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are histamine H4 receptor inhibitors useful in the treatment of histamine H4 receptor-associated conditions or diseases or disorders including, for example, inflammatory diseases or disorders, pruritus, and pain.

  本发明涉及式I或式XI的取代杂环化合物：或其药学上可接受的盐或N-氧化物或季铵盐，其中成员构成在此提供，以及它们的组合物和使用方法，它们是组胺H4受体抑制剂，用于治疗组胺H4受体相关的疾病或疾病或疾病，包括例如，炎症性疾病或疾病，瘙痒和疼痛。
• Synthesis and bioactivities of novel piperidylpyrimidine derivatives: inhibitors of tumor necrosis factor-alpha production
  作者：Norio Fujiwara、Hitoshi Fujita、Kiyotaka Iwai、Ayumu Kurimoto、Shinobu Murata、Hajime Kawakami

  DOI：10.1016/s0960-894x(00)00227-4

  日期：2000.6

  New piperidylpyrimidine derivatives, including quinazolines, were prepared, and their abilities to inhibit TNF-alpha production evaluated. Some compounds showed potent inhibitory activity in mouse macrophages stimulated with LPS. The synthesis and structure-activity relationships of these compounds are described. (C) 2000 Elsevier Science Ltd. All rights reserved.
• Ligand based design of novel histamine H4 receptor antagonists; fragment optimization and analysis of binding kinetics
  作者：Rogier A. Smits、Herman D. Lim、Tiffany van der Meer、Sebastiaan Kuhne、Karin Bessembinder、Obbe P. Zuiderveld、Maikel Wijtmans、Iwan J.P. de Esch、Rob Leurs

  DOI：10.1016/j.bmcl.2011.10.104

  日期：2012.1

  The histamine H-4 receptor is a G protein-coupled receptor that has attracted much interest for its role in inflammatory and immunomodulatory functions. In our search for new H4R ligands, a low affinity isoquinoline fragment was optimized to 7-(furan-2-yl)-4-(piperazin-1-yl)quinazolin-2-amine (VUF11489), as a new H4R antagonist. Analysis of its binding kinetics at the human H4R showed this compound to have a very different dissociative half-life in comparison with reference antagonist JNJ7777120. (C) 2011 Elsevier Ltd. All rights reserved.